Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models

Abstract

Abnormal Ca2+ handling is essential in the pathophysiology of degenerative muscle disorders, such as dilated cardiomyopathy (DCM) and muscular dystrophy (MD). Transient receptor potential cation channel, subfamily V, member 2 (TRPV2) is a candidate for Ca2+ entry and a potential therapeutic target for degenerative muscle disorders, there are few specific inhibitors for TRPV2. In this study, we produced a monoclonal antibody (designated mAb88-2) and two polyclonal antibodies (pAb591 and pAb592) that selectively recognize TRPV2 from the outside of cells and interact with the turret region of the pore-forming outer gate. These antibodies inhibited Ca2+ influx via TRPV2 in cultured cells and substantially reduced TRPV2 in the plasma membrane via cellular internalization. We evaluated the therapeutic efficacy of the functional antibody in δ-sarcoglycan-deficient hamster (J2N-k) models of DCM and MD and in the 4C30 DCM model of murine heart failure. The intraperitoneal administration of the functional antibody (0.5 mg/kg) for 2 weeks (once a week) prevented the progression of cardiac dysfunction, as evaluated by echocardiography and histological staining, and improved the abnormal Ca2+ handling (high diastolic Ca2+ level and small Ca2+ transient peak) in cardiomyocytes isolated from J2N-k hamsters and prevented skeletal muscle damage. Further, the antibody effectively prevented heart failure in the 4C30 mouse model with end-stage DCM. Interestingly, endogenous TRPV2 that accumulated in the cardiac and skeletal muscle sarcolemma disappeared upon antibody administration. Thus, the newly produced antibodies are capable of ameliorating DCM and MD by promoting the cellular internalization of TRPV2; antibodies specific to human TRPV2 may substantially improve the treatment of patients with degenerative muscle diseases.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Produced monoclonal and polyclonal antibodies recognize TRPV2 from the extracellular side.
Fig. 2: Produced antibodies inhibits TRPV2-dependent Ca2+ response from the outside.
Fig. 3: Antibody production and epitope mapping.
Fig. 4: Prevention of skeletal muscle damage by TRPV2-neutralizing antibodies in dystrophic hamsters.
Fig. 5: TRPV2 localization and the effect of mAb88-2 on Ca2+ response in isolated cardiomyocytes from hamsters.
Fig. 6: Protection against cardiac dysfunction by mAb88-2 administration in J2N-k hamsters.
Fig. 7: Protection against dilated cardiomyopathy by mAb88-2 administration in the mouse model 4C30.

References

  1. 1.

    Hughes SE, McKenna WJ. New insights into the pathology of inherited cardiomyopathy. Heart. 2005;91:257–64.

  2. 2.

    Fatkin D, Graham RM. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev. 2002;82:945–80.

  3. 3.

    Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104:557–67.

  4. 4.

    Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375:752–62.

  5. 5.

    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.

  6. 6.

    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.

  7. 7.

    Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782–95.

  8. 8.

    Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature. 1989;338:259–62.

  9. 9.

    Campbell KP. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell. 1995;80:675–9.

  10. 10.

    McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res. 2017;121:731–48.

  11. 11.

    Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, Politano L, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet. 1997;6:601–7.

  12. 12.

    Nakamura TY, Iwata Y, Sampaolesi M, Hanada H, Saito N, Artman M, et al. Stretch-activated cation channels in skeletal muscle myotubes from sarcoglycan-deficient hamsters. Am J Physiol Cell Physiol. 2001;281:C690–9.

  13. 13.

    Sampaolesi M, Yoshida T, Iwata Y, Hanada H, Shigekawa M. Stretch-induced cell damage in sarcoglycan-deficient myotubes. Pflugers Arch. 2001;442:161–70.

  14. 14.

    Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel. J Cell Biol. 2003;161:957–67.

  15. 15.

    Iwata Y, Ohtake H, Suzuki O, Matsuda J, Komamura K, Wakabayashi S. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy. Cardiovasc Res. 2013;99:760–8.

  16. 16.

    Iwata Y, Katanosaka Y, Arai Y, Shigekawa M, Wakabayashi S. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum Mol Genet. 2009;18:824–34.

  17. 17.

    Iwata Y, Katayama Y, Okuno Y, Wakabayashi S. Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model. Oncotarget. 2018;9:14042–57.

  18. 18.

    Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10:e8689.

  19. 19.

    Mandal AK, Mercado A, Foster A, Zandi-Nejad K, Mount DB. Uricosuric targets of tranilast. Pharmacol Res Perspect. 2017;5:e00291.

  20. 20.

    Suzuki O, Kanai T, Nishikawa T, Yamamoto Y, Noguchi A, Takimoto K, et al. Adult onset cardiac dilatation in a transgenic mouse line with Galbeta1,3GalNAc alpha2,3-sialyltransferase II (ST3Gal-II) transgenes: a new model for dilated cardiomyopathy. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:550–62.

  21. 21.

    Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res. 2008;103:891–9.

  22. 22.

    Maekawa K, Hirayama A, Iwata Y, Tajima Y, Nishimaki-Mogami T, Sugawara S, et al. Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J Mol Cell Cardiol. 2013;59:76–85.

  23. 23.

    Kuhara M, Yoshino T, Shiokawa M, Okabe T, Mizoguchi S, Yabuhara A, et al. Magnetic separation of human podocalyxin-like protein 1 (hPCLP1)-positive cells from peripheral blood and umbilical cord blood using anti-hPCLP1 monoclonal antibody and protein A expressed on bacterial magnetic particles. Cell Struct Funct. 2009;34:23–30.

  24. 24.

    Iwata Y, Katanosaka Y, Shijun Z, Kobayashi Y, Hanada H, Shigekawa M, et al. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol. 2005;70:740–51.

  25. 25.

    Huynh KW, Cohen MR, Jiang J, Samanta A, Lodowski DT, Zhou ZH, et al. Structure of the full-length TRPV2 channel by cryo-EM. Nat Commun. 2016;7:11130.

  26. 26.

    Zheng J, Ma L. Structure and function of the thermoTRP channel pore. Curr Top Membr. 2014;74:233–57.

  27. 27.

    Hutchings CJ, Colussi P, Clark TG. Ion channels as therapeutic antibody targets. MAbs. 2019;11:265–96.

  28. 28.

    Wilkinson TC, Gardener MJ, Williams WA. Discovery of functional antibodies targeting ion channels. J Biomol Screen. 2015;20:454–67.

  29. 29.

    Haustrate A, Hantute-Ghesquier A, Prevarskaya N, Lehen'kyi V. Monoclonal antibodies targeting ion channels and their therapeutic potential. Front Pharmacol. 2019;10:606.

  30. 30.

    Wilkinson TC, Gardener MJ, Williams WA. Discovery of functional antibodies targeting ion channels. J Biomol Screen. 2019;20:454–67.

  31. 31.

    Ching KH, Collarini EJ, Abdiche YN, Bedinger D, Pedersen D, Izquierdo S, et al. Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets. MAbs. 2018;10:71–80.

  32. 32.

    Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010;2:594–606.

  33. 33.

    Zubcevic L, Herzik MA Jr., Chung BC, Liu Z, Lander GC, Lee SY. Cryo-electron microscopy structure of the TRPV2 ion channel. Nat Struct Mol Biol. 2016;23:180–6.

  34. 34.

    Juvin V, Penna A, Chemin J, Lin YL, Rassendren FA. Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate. Mol Pharmacol. 2007;72:1258–68.

  35. 35.

    Klionsky L, Tamir R, Holzinger B, Bi X, Talvenheimo J, Kim H, et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J Pharmacol Exp Ther. 2006;319:192–8.

  36. 36.

    Lorin C, Vogeli I, Niggli E. Dystrophic cardiomyopathy: role of TRPV2 channels in stretch-induced cell damage. Cardiovasc Res. 2015;106:153–62.

  37. 37.

    Cox JH, Hussell S, Sondergaard H, Roepstorff K, Bui JV, Deer JR, et al. Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function. PLoS One. 2013;8:e82944.

  38. 38.

    Sun H, Luo L, Lal B, Ma X, Chen L, Hann CL, et al. A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis. Nat Commun. 2016;7:10339.

  39. 39.

    Studzian M, Bartosz G, Pulaski L. Endocytosis of ABCG2 drug transporter caused by binding of 5D3 antibody: trafficking mechanisms and intracellular fate. Biochim Biophys Acta. 2015;1853:1759–71.

  40. 40.

    Shcherbatko A, Foletti D, Poulsen K, Strop P, Zhu G, Hasa-Moreno A, et al. Modulation of P2X3 and P2X2/3 receptors by monoclonal antibodies. J Biol Chem. 2016;291:12254–70.

  41. 41.

    Koch SE, Mann A, Jones S, Robbins N, Alkhattabi A, Worley MC, et al. Transient receptor potential vanilloid 2 function regulates cardiac hypertrophy via stretch-induced activation. J Hypertens. 2017;35:602–11.

  42. 42.

    Entin-Meer M, Levy R, Goryainov P, Landa N, Barshack I, Avivi C, et al. The transient receptor potential vanilloid 2 cation channel is abundant in macrophages accumulating at the peri-infarct zone and may enhance their migration capacity towards injured cardiomyocytes following myocardial infarction. PLoS One. 2014;9:e105055.

  43. 43.

    Entin-Meer M, Cohen L, Hertzberg-Bigelman E, Levy R, Ben-Shoshan J, Keren G. TRPV2 knockout mice demonstrate an improved cardiac performance following myocardial infarction due to attenuated activity of peri-infarct macrophages. PLoS One. 2017;12:e0177132.

  44. 44.

    Jones S, Mann A, Worley MC, Fulford L, Hall D, Karani R, et al. The role of transient receptor potential vanilloid 2 channel in cardiac aging. Aging Clin Exp Res. 2017;29:863–73.

  45. 45.

    Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301–16.

  46. 46.

    Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87.

  47. 47.

    Matsumura T, Matsui M, Iwata Y, Asakura M, Saito T, Fujimura H, et al. A pilot study of tranilast for cardiomyopathy of muscular dystrophy. Intern Med. 2018;57:311–8.

  48. 48.

    Moore BJR, Islam B, Ward S, Jackson O, Armitage R, Blackburn J, et al. Repurposing of tranilast for potential neuropathic pain treatment by inhibition of sepiapterin reductase in the BH4 pathway. ACS Omega. 2019;4: 11960−72.

Download references

Acknowledgements

We would like to thank Mrs Hitomi Ohtake and Madoka Hirayama for technical assistance. We would also like to thank Dr Ryu Nagata (Osaka University) for helpful discussions and Dr Kiichiro Tomoda (Osaka Medical Collage) for technical assistance with the structural modeling of mTRPV2. This work was funded by the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C) [grant number 17K09598 to YI] and Grant-in-Aid for Research on Nervous and Mental Disorders of NCNP [grant number 28-6 to YI].

Author information

Correspondence to Yuko Iwata.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Iwata, Y., Wakabayashi, S., Ito, S. et al. Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models. Lab Invest 100, 324–337 (2020). https://doi.org/10.1038/s41374-019-0363-1

Download citation